Clinical trial
The βIG-H3 Protein: a New Marker in PANCreatic Adenocarcinoma
NCT03472716 is registered in ClinicalTrials.gov with Centre Leon Berard as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The βIG-H3 Protein: a New Marker in PANCreatic Adenocarcinoma
- Lead sponsor
- Centre Leon Berard
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- May 22, 2018
- Completion date
- September 30, 2023
- Enrollment
- 80 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
pancreas adenocarcinoma